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The in vivo incorporation of [3H]phenylalanine into an apparent 15 kDa prosomatostatin was observed in 
the hypothalamus of rats injected with the labeled amino acid in the third ventricle. Precursor-product 
relationships were established between this newly synthesized material and both somatostatin-28 and -14. 
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1. INTRODUCTION 
Somatostatin (somatostatin-14) is a tetradeca- 
peptide hormone present in both neural and 
gastrointestinal tracts [l-3]. In the central nervous 
system, it is distributed throughout various brain 
areas [4] together with another form: somato- 
statin- [5]. Somatostatin-28, first discovered in 
both porcine intestine [6] and hypothalamus [7] 
and in ovine hypothalamus [8,9], corresponds to 
an NHz-terminally extended somatostatin-14 con- 
taining 28 amino acids. 
Hypothalamus, where somatostatin-positive cell 
bodies are clustered within the periventricular 
nuclei [lO,l 11, has been extensively used to study 
the neural biosynthesis of both somatostatin-14 
and -28. An immunoreactive material with an ap- 
parent M, = 15 000 was identified in mouse [ 121 and 
rat [ 131 hypothalamic extracts. In contrast with the 
situation encountered in the pancreas [14,15] this 
material consists of a single, predominant, form 
which was converted into both somatostatin-14 
and -28 by incubation with hypothalamic enzymes 
[16]. A preprosomatostatin was identified by 
Abbreviations: SDS-PAGE, SDS-polyacrylamide gel 
electrophoresis; HPLC, high-pressure liquid chroma- 
tography; TFA, trifluoroacetic acid 
translating, in a cell-free system, either rodent [17] 
or bovine [ 181 hypothalamic mRNAs. The presence 
of microsomal membranes during the translation 
yielded a proprotein with a MI - 15 000 [ 181. Hypo- 
thalamic neurones kept in culture incorporated 
labelled amino acids into an immunoreactive form 
(M, - 15 000) which decreased uring a chase period 
while somatostatin-14 and -28 appeared [ 191. All 
these results suggest strongly that both hypotha- 
lamic somatostatin-14 and -28 are synthesized via 
a common precursor with ik&- 15 000. Never- 
theless, up to now, no in vivo precursor-product 
relationship between a newly synthesized form and 
somatostatin-14 and -28 has been reported. 
Therefore, we have attempted to establish this by 
performing pulse-chase xperiments in the rat. The 
results we have obtained indicate that an im- 
munoreactive form with A+ 15000 was detected 
and that it behaves as a biosynthetic precursor. 
2. MATERIALS AND METHODS’ 
Male Wistar rats (260 g, Iffa-Credo, France) were 
anesthesized with sodium pentobarbital (45-60 
mg/kg, i.p., Clin-Midy, France). 200 &i L- 
[2,3,4,5,6-3H]phenylalanine (130 Ci/mmol, Amer- 
sham, England), concentrated by lyophilisation 
then dissolved in 2 pl of 150 mM NaCl, were in- 
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jetted into the third ventricle of each animal using 
a stereotaxic device (David Kopf Instruments, 
USA) and according to [20]” 
After the chase period, the rats were decapitated, 
the brains were removed then the whole hypothal- 
ami were dissected as in [Zl] and homoge~ed in 
0.1 N HQ containing 8 Mwurea, 4pg/mf aprotinin, 
1 aglml of pepstatin and 5 mM phenylmethyl- 
sulfonyl fluoride. After extraction (16 h) the ho- 
mogenate was centrifuged at 100 00 x g for 60 min 
in a Beckmatl LS-50 ultracentrifuge. The supernate 
was fractionated on a Sephadex G-50 column 
(1.2 x 100 cm) equilibrated with 0.1 N formic acid 
and precalibrated according to [5]. 
Eluate containing proteins with M, 10 000-25 000 
was pooled and somatostatin-like species were 
isolated by ~munopr~ipitatio~. Antisomatostatin 
antiserum 36-36 (a generous gift of C. Rougeot, 
URIA, Institut Pasteur, Paris) was used at a final 
dilution of 1: 6 after IgG chromatographic separa- 
tion on DEAF,-trisacryl. Finally, immunoprecipi- 
tated proteins were analyzed by SDS-PAGE, Im- 
munoprecipitation and SDS-PAGE were carried 
out as in 1221. 
Fractions from the filtration on Sephadex G-50 
which contained together peptides with MA 10000 
and low Mr molecules such as urea and t3H]phenyl- 
alanine were pooled and passed through a Sep-Pak 
Cl8 cartridge (Water Associates, Milford, MA). 
By washing with 0.1% TFA, urea and 13H]phenyl- 
alanine were removed and then the adsorbed pep- 
tides were eluted with 80% acetonitrile in 0.1% 
TFA. After elimination of acetonitrile and TFA by 
evaporation in a savant Speed Vat concentrator, 
the ~matosta~n-like p ptides were isolated by im- 
munoaf~~ty chromato~aphy as described 1121, 
then identified by HPLC using a Beckman system 
421. Analyses were performed on a pBondapak 
Cl8 column (3.9 x 300 mm) with 25% acetonitrile 
in 100 mM triethylammonium phosphate (pH 3) as 
solvent at 1 mllmin, Somatastat~-~4 and -28 ob- 
tained through CRB (Cambridge, England) were 
used as standards. 
Protein concentration was determined according 
to Lowry et al. [23]. 
3. RESULTS 
Based on available data in the literature the 
hypothalamic precursor of both somatostatin-14 
and -28 should be expected as a protein with 
M,- 15 000. Therefore, during a pulse-chase ex- 
periment, this protein should be detected early 
then its disappearance should be concomitant with 
increase in both somatostatin-14 and -28. 
To perform the in viva iabeling experiment 
~3H]phenyl~~ine was injected into rat third ven- 
tricle and the protein content of hypothalamic ex- 
tracts was analyzed at various times thereafter. 
Preliminary experiments were carried out with 
f’S]cysteine then f3H]phenylalanine was used ow- 
ing to its better incor~ra~on into proteins. The 
third ventricule was selected as injection site 
because the somatostatin-producing cellbodies are 
essentially ocated in the periventricular ea sur- 
rounding the third ventricule [lO,ll]. After the 
chase period, the extract was prepared from the 
whole hothead in order to detect both the 
precursor produced by the ~~ventricular pericarya 
and the final products transported tovarious hypo- 
thalamic areas, 
The radioactive proteins and peptides of the ex- 
tracts were chemically characterized by both SDS- 
PAGE and reverse-phase HPLC, respectively. 
They were previously selected by gei filtration and 
purified by either immunoprecipitation r affinity 
chromatography. Proteins were recovered as a 
unique peak corresponding to species with Mr 
15 Ooo f 10%. This peak disappeared when 
i~unopr~ipi~tion was carried out in the 
presence of somatostatin-14 (fig. I). Peptides were 
recovered as two peaks identified as so- 
matostatin-14 and -28 as coeluted with synthetic 
standards (fig.2)). 
To establish a pr~ursor-pr~uct relationship 
between the protein with M+ 15 000 and somato- 
statin- and -28, the radioactivity of these species 
was measured as a function of the chase period. 30 
min after [‘Hlphenylalanine injection, a protein 
with A&- 15000 was the only one detected, Its 
radioacti~ty increased for 1 h then decreased and 
disappeared at 4 h (fig.3). Somatostatin-14 was 
detected after 2 h whereas somatostatin-28 ap- 
peared later, after 4 h, After 20 h, the radioactivi- 
ty of each peptide was approximately the same as 
after 4 h with the somatostatin-28 value lower than 
that of somatostatin-14. Taken together, these 
variations in radioactivity incorporated into the 
protein with Mr- 15 000 and somatostatin-14 and 
-28 are consistent with the early synthesis of a 
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Fig. 1. SDS-PAGE of the 3H-labelled somatostatin-like 
proteins extracted from 5 rat hypothalami 1 h after the 
injection of [“H]phenylalanine into the third ventricle. 
The material was immunoprecipitated with antisomato- 
statin- antibodies both in the presence (0) and absence 
(0) of 10 pg somatostatin-14. MoIecular mass markers 
(in kDa): carbonic anhydrase (29); soybean trypsin in- 
hibitor (21); lysozyme (14.3). f, migration of bromo- 
phenol blue. 
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Fig.2. Reverse-phase HPLC of the ‘H-labelled somato- 
statin-like peptides extracted from 5 rat hypothalami 4 h 
after the injection of ~3H]phenyl~anine into the third 
ventricule and purified by i~unoaffinity chroma- 
tography. Column, Bondapak Cl8 (3.9 x 300 mm); iso- 
cratic solvent, 25% acetonitrile in 100 mM triethylam- 
monium phosphate, pH 3; flow rate, 1 ml/min; frac- 
tions, 1 ml. The elution volumes of both synthetic 
somatostatin-14 (S-14) and somatostatin-28 (S-28) are 
indicated by arrows. 
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Fig.3. Radioactivity incorporated into prosomatostatin 
(Mr-15000) (o), somatostatin-14 (0) and somato- 
statin- (a) at various times after the injection of 
[“H]phenylalanine into the rat third ventricule. Each 
plotted value corresponds to the mean radioactivity of 2 
or 3 successive xperiments carried out with 5 rats each. 
precursor molecule and its subsequent processing 
into final products. 
An additional radioactive somatostatin-like peak 
was occasionally detected on SDS-PAGE after 2,4 
and 20 h, respectively. It was located in the range 
n/r, 8000-10000. It was not detected after a short 
period of chase (30 min and 1 h). 
4. DISCUSSION 
Pulse-chase experiments are suitable for study- 
ing the biosynthesis of peptides arising from pre- 
cursors but some difficulties can be encountered 
when they are performed in vivo. The presence of 
unlabelled amino acid in the tissues may have a 
negative effect on the incorporation by decreasing 
the radioactivity of the injected amino acid. In 
tissues where the protein synthesis is multiple, the 
radioactivity incorporated into each protein can be 
very low. Although, in our experiments, radioac- 
tive somatostatin-like proteins represented only 
0.~5~0 of the total radioactive proteins, it was 
nevertheless possible to isolate and analyze them. 
In the same way, radioactive somatostatin-14 and 
-28 (0.5% of the total radioactive peptides) could 
be purified and characterized. The results obtained 
show unambiguously that somatostatin-14 and -28 
derive from a precursor with M, 15 000. So, the in 
16 
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vivo synthesis seems to proceed as indicated by the 
in vitro experiments [12,13,16-191. 
Two points remain unresolved. The first con- 
cerns the size of the prosomatostatin. The experi- 
mental values correspond to M,- 15 000. On the 
other hand, Goodman et al. [24] calculated a 
A4, = 10 388 from the sequence of a rat thyroid car- 
cinoma preprosomatostatin deduced from the 
cDNA sequence. A post-translational modification 
could be responsible for this discrepancy. Glyco- 
sylation has been evoked but seems unlikely [24]. 
Another possibility is that prosomatostatin pos- 
sesses a particular conformation resulting in an 
anomalous behavior in both SDS-PAGE and gel 
filtration. 
The second point concerns the processing of 
prosomatostatin into both somatostatin-14 and 
-28. Somatostatin-28 is generally considered as an 
intermediate between prosomatostatin and 
somatostatin-14. A conversion enzyme has been 
characterized in rat brain extracts which produces 
in vitro somatostatin-14 from somatostatin-28 
[25-271. On the other hand, it appears that 
somatostatin-14 can be generated directly from 
prosomatostatin. Benoit et al. [28] characterized a 
peptide in rat brain extracts which should corre- 
spond to the whole prosomatostatin molecule 
devoid of the Arg-Lys-somatostatin-14 COOH- 
terminal fragment. If somatostatin-28 generates 
somatostatin-14, a precursor-product relationship 
between the two peptides should be observed dur- 
ing a pulse-chase. In our experiments this was not 
apparent. Somatostatin-14 was detected at first as 
if it was produced directly from prosomatostatin. 
Nevertheless, the alternative possibility that 
somatostatin-28 could be formed, then immediate- 
ly, and rapidly converted to somatostatin-14 can- 
not be excluded. In addition, a low incorporation 
of radioactivity into somatostatin-28 might remain 
undetected under our experimental conditions. In 
contrast, with its late appearance, somatostatin-28 
remains present as well as somatostatin-14 after 
20 h. This fact, and the absence of a precursor- 
product relationship between somatostatin-14 and 
-28, suggest as previously proposed by Van Itallie 
and Fernstrom [29] that somatostatin-28 is at least 
in part a ‘final’ product in the hypothalamus. So, 
the processing of the prosomatostatin is a com- 
plicated phenomenon. Moreover, other peptides, 
resulting from other cleavages at still unidentified 
loci can be generated. In our experiments another 
somatostatin-like peptide was detected after 2 h. 
According to its apparent M, it could possibly arise 
from a cleavage at position 56-57 of the 
preprosomatostatin sequence [24]. 
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